Roche automates next-gen sequencing sample prep

By Andre Rickard, The Science Advisory Board contributing writer

December 14, 2021 -- Roche announced the launch of the Avenio Edge System, a core component of Roche's strategy to advance sequencing technologies. The system is built on Roche's foundational capabilities to deliver a fully automated, integrated sequencing solution.

Avenio Edge is a preanalytical platform for sequencing library preparation, target enrichment, and quantification steps that deliver integrated, end-to-end control with reliable, consistent, high-quality results, according to the firm.

Next-generation sequencing samples are delicate, and every step of sample preparation has the potential to impact results. The Avenio Edge System's high reproducibility and low error rate can support a laboratory's goal of reducing the number of rejected samples that otherwise might have to be recollected.

The system features ready-to-use components in addition to customizable workflow parameters, making it a scalable, cost-efficient solution for sequencing laboratories seeking high performance and agility. This Avenio Edge System has demonstrated a more than a 96% lower error opportunity and an 84% reduction in hands-on time. In addition, Avenio Edge has a setup to initiation time of 20 minutes.

The Avenio Edge System will be available at select locations worldwide with timelines that vary by country.

Recursion, Roche, Genentech to use machine learning, HCS to drive discovery
Recursion is set to collaborate with Roche and Genentech in the fields of neuroscience and oncology to advance new medicines for patients using large-scale...
Roche releases genomic profiling kit for cancer research
Roche has released a new genomic profiling kit for cancer research called the Avenio Tumor Tissue Comprehensive Genomic Profiling kit.
Adaptimmune collaborates with Genentech on allogeneic T-cell therapies
Adaptimmune Therapeutics is joining forces with Genentech, a Roche company, to develop and commercialize allogeneic T-cell therapies for multiple oncologic...
Shape Therapeutics, Roche to advance AAV-based RNA editing tech
Shape Therapeutics and Roche have inked a strategic collaboration and licensing agreement to develop gene therapies for Alzheimer's disease, Parkinson's...
FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter